For Patients

MelaGenix is a gene expression test that measures the activity profile of eight disease-relevant genes in the melanoma and surrounding skin tissue. The MelaGenix result identifies your relapse risk within the next few years.
The MelaGenix gene expression test is particularly suited for patients who have been diagnosed with early or intermediate stage (I and II) cutaneous malignant melanoma. MelaGenix can also greatly contribute to planning the treatment of patients who have been diagnosed with 'imminent metastases' (stage III).
Once you have been diagnosed, you will discuss various forms of treatment with your physician.

In order to be able to assess for you the risks and benefits of potential forms of treatment, you should know about your exact personal relapse risk within the next few years. Therefore, in consultation with your physician you should perform the MelaGenix gene expression test as soon as possible after diagnosis to obtain more security in designing your individual treatment and follow-up care plan. MelaGenix can also be very useful in obtaining more certainty for the further planning of your life if some time has passed since your diagnosis.
The MelaGenix gene expression test supplements the classical tissue diagnosis with your individual tumor biology and supports you and your physician in more precisely estimating your personal relapse risk. The MelaGenix risk value can result in a completely new classification of your relapse risk depending on the melanoma stage and thus protects you from an undersupply of treatment as well as from an oversupply. This helps to applicate treatments in a more targeted manner and thereby avoids unnecessary side effects. MelaGenix moreover provides you with more security in the individual design of your melanoma treatment.

Your physician will be happy to explain the significance of the individual MelaGenix test report results regarding your further treatment. NeraCare will not provide a corresponding treatment plan to match your ascertained test result.
The MelaGenix gene expression test does not require surgical intervention. The gene activity analysis is carried out using the available primary tumor tissue that was routinely preserved after your surgery. The test measures the activity profile of eight disease-relevant genes in the melanoma and surrounding skin tissue. The MelaGenix result identifies your relapse risk within the next few years.
After your physician has ordered the MelaGenix gene expression test, NeraCare will request the tissue sample of your primary melanoma from the relevant pathology laboratory. Subsequently, NeraCare performs the MelaGenix Test under certified and accredited conditions in a molecular biology laboratory and determines your personal risk score.

Please contact your consulting physician should you decide to have the MelaGenix gene expression test performed. MelaGenix is prescribed and requested by your physician.
The test result will usually be sent to your consulting physician within 2 to 3 weeks.
The MelaGenix gene expression test has been available since 2015 and some private insurances in Germany already reimburse the costs of the test on a case-to-case basis.

Patients would have to initially shoulder the full cost of the gene test. A 50% down payment is required through money transfer or credit card upon placement of the order. The remaining 50% is due upon delivery of the MelaGenix Risk Score to your consulting physician. Depending on your country, some private health insurances and medical aid authorities may be willing to cover the costs of the gene test. Please contact your insurance provider for information on reimbursement options.

Please contact us under info@neracare.com in the event of questions regarding the cost reimbursement procedure.